Lower levels of urinary 2-hydroxyestrogens in polycystic ovary syndrome

Sana Salih, Xia Xu, Timothy D. Veenstra, Antoni J. Duleba, Hala Fouad, Manubai Nagamani, Ayman Al-Hendy

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Context: Women with polycystic ovary syndrome (PCOS) have anovulation due to arrested follicular maturation. The substrate (2-hydroxyestrogen) and product (2-methoxyestrogen) of catechol-O-methyl transferase (COMT) have been shown to modulate proliferation and angiogenesis of granulosa cells. Objective: The objective of the study was to evaluate COMT ovarian expression as well as the production of estrogen metabolites (2-hydroxyestrogen and 2-methoxyestrogen) in subjects with PCOS. Design: Immunohistochemistry was used to assess COMT expression in ovarian tissues. Urinary levels of 10 different estrogens and estrogen metabolites were measured using enzyme-labeled immunoassays and/or liquid chromatography with tandem mass spectrometry. Setting: The study was conducted at a tertiary university referral center. Patients and Other Participants: Ovarian tissues were obtained from six control subjects and six subjects with PCOS. Fasting first-void urinary samples were collected from 49 subjects with PCOS and 36 healthy control subjects. Main Outcome Measure(s): COMT protein expression in ovarian tissues was measured. Urinary levels of 2-hydroxyestrogen and 2-methoxyestrogen levels in PCOS patients were also measured. Results: Whereas immunohistochemistry showed that COMT was expressed in ovaries from control and PCOS subjects, its expression was significantly higher in ovaries from subjects with PCOS, in both the follicular structures and ovarian stroma. The urinary 2-hydroxyestrogen level was significantly lower in subjects with PCOS, compared with normal controls (P = 0.009). Additionally, urinary 2-hydroxyestrogen levels negatively correlated with serum insulin levels in subjects with PCOS (r = -0.333, P =0 .031). Conclusions: Urinary 2-hydroxyestrogen is decreased in subjects with PCOS, which could be due in part to increased ovarian expression of COMT. Further studies are needed to ascertain the role of estrogen metabolism in PCOS before this information can be used in clinical settings.

Original languageEnglish (US)
Pages (from-to)3285-3291
Number of pages7
JournalJournal of Clinical Endocrinology and Metabolism
Volume92
Issue number8
DOIs
StatePublished - Aug 2007

Fingerprint

Polycystic Ovary Syndrome
Transferases
Guaiacol
Estrogens
Tissue
Metabolites
Liquid chromatography
Metabolism
Ovary
Mass spectrometry
catechol
Immunohistochemistry
Anovulation
Insulin
Granulosa Cells
Tandem Mass Spectrometry
Immunoenzyme Techniques
Tertiary Care Centers
Substrates
Enzymes

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Salih, S., Xu, X., Veenstra, T. D., Duleba, A. J., Fouad, H., Nagamani, M., & Al-Hendy, A. (2007). Lower levels of urinary 2-hydroxyestrogens in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 92(8), 3285-3291. https://doi.org/10.1210/jc.2006-2719

Lower levels of urinary 2-hydroxyestrogens in polycystic ovary syndrome. / Salih, Sana; Xu, Xia; Veenstra, Timothy D.; Duleba, Antoni J.; Fouad, Hala; Nagamani, Manubai; Al-Hendy, Ayman.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 92, No. 8, 08.2007, p. 3285-3291.

Research output: Contribution to journalArticle

Salih, S, Xu, X, Veenstra, TD, Duleba, AJ, Fouad, H, Nagamani, M & Al-Hendy, A 2007, 'Lower levels of urinary 2-hydroxyestrogens in polycystic ovary syndrome', Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 8, pp. 3285-3291. https://doi.org/10.1210/jc.2006-2719
Salih, Sana ; Xu, Xia ; Veenstra, Timothy D. ; Duleba, Antoni J. ; Fouad, Hala ; Nagamani, Manubai ; Al-Hendy, Ayman. / Lower levels of urinary 2-hydroxyestrogens in polycystic ovary syndrome. In: Journal of Clinical Endocrinology and Metabolism. 2007 ; Vol. 92, No. 8. pp. 3285-3291.
@article{1b670ef3b36f42efa31121d0d927389f,
title = "Lower levels of urinary 2-hydroxyestrogens in polycystic ovary syndrome",
abstract = "Context: Women with polycystic ovary syndrome (PCOS) have anovulation due to arrested follicular maturation. The substrate (2-hydroxyestrogen) and product (2-methoxyestrogen) of catechol-O-methyl transferase (COMT) have been shown to modulate proliferation and angiogenesis of granulosa cells. Objective: The objective of the study was to evaluate COMT ovarian expression as well as the production of estrogen metabolites (2-hydroxyestrogen and 2-methoxyestrogen) in subjects with PCOS. Design: Immunohistochemistry was used to assess COMT expression in ovarian tissues. Urinary levels of 10 different estrogens and estrogen metabolites were measured using enzyme-labeled immunoassays and/or liquid chromatography with tandem mass spectrometry. Setting: The study was conducted at a tertiary university referral center. Patients and Other Participants: Ovarian tissues were obtained from six control subjects and six subjects with PCOS. Fasting first-void urinary samples were collected from 49 subjects with PCOS and 36 healthy control subjects. Main Outcome Measure(s): COMT protein expression in ovarian tissues was measured. Urinary levels of 2-hydroxyestrogen and 2-methoxyestrogen levels in PCOS patients were also measured. Results: Whereas immunohistochemistry showed that COMT was expressed in ovaries from control and PCOS subjects, its expression was significantly higher in ovaries from subjects with PCOS, in both the follicular structures and ovarian stroma. The urinary 2-hydroxyestrogen level was significantly lower in subjects with PCOS, compared with normal controls (P = 0.009). Additionally, urinary 2-hydroxyestrogen levels negatively correlated with serum insulin levels in subjects with PCOS (r = -0.333, P =0 .031). Conclusions: Urinary 2-hydroxyestrogen is decreased in subjects with PCOS, which could be due in part to increased ovarian expression of COMT. Further studies are needed to ascertain the role of estrogen metabolism in PCOS before this information can be used in clinical settings.",
author = "Sana Salih and Xia Xu and Veenstra, {Timothy D.} and Duleba, {Antoni J.} and Hala Fouad and Manubai Nagamani and Ayman Al-Hendy",
year = "2007",
month = "8",
doi = "10.1210/jc.2006-2719",
language = "English (US)",
volume = "92",
pages = "3285--3291",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "8",

}

TY - JOUR

T1 - Lower levels of urinary 2-hydroxyestrogens in polycystic ovary syndrome

AU - Salih, Sana

AU - Xu, Xia

AU - Veenstra, Timothy D.

AU - Duleba, Antoni J.

AU - Fouad, Hala

AU - Nagamani, Manubai

AU - Al-Hendy, Ayman

PY - 2007/8

Y1 - 2007/8

N2 - Context: Women with polycystic ovary syndrome (PCOS) have anovulation due to arrested follicular maturation. The substrate (2-hydroxyestrogen) and product (2-methoxyestrogen) of catechol-O-methyl transferase (COMT) have been shown to modulate proliferation and angiogenesis of granulosa cells. Objective: The objective of the study was to evaluate COMT ovarian expression as well as the production of estrogen metabolites (2-hydroxyestrogen and 2-methoxyestrogen) in subjects with PCOS. Design: Immunohistochemistry was used to assess COMT expression in ovarian tissues. Urinary levels of 10 different estrogens and estrogen metabolites were measured using enzyme-labeled immunoassays and/or liquid chromatography with tandem mass spectrometry. Setting: The study was conducted at a tertiary university referral center. Patients and Other Participants: Ovarian tissues were obtained from six control subjects and six subjects with PCOS. Fasting first-void urinary samples were collected from 49 subjects with PCOS and 36 healthy control subjects. Main Outcome Measure(s): COMT protein expression in ovarian tissues was measured. Urinary levels of 2-hydroxyestrogen and 2-methoxyestrogen levels in PCOS patients were also measured. Results: Whereas immunohistochemistry showed that COMT was expressed in ovaries from control and PCOS subjects, its expression was significantly higher in ovaries from subjects with PCOS, in both the follicular structures and ovarian stroma. The urinary 2-hydroxyestrogen level was significantly lower in subjects with PCOS, compared with normal controls (P = 0.009). Additionally, urinary 2-hydroxyestrogen levels negatively correlated with serum insulin levels in subjects with PCOS (r = -0.333, P =0 .031). Conclusions: Urinary 2-hydroxyestrogen is decreased in subjects with PCOS, which could be due in part to increased ovarian expression of COMT. Further studies are needed to ascertain the role of estrogen metabolism in PCOS before this information can be used in clinical settings.

AB - Context: Women with polycystic ovary syndrome (PCOS) have anovulation due to arrested follicular maturation. The substrate (2-hydroxyestrogen) and product (2-methoxyestrogen) of catechol-O-methyl transferase (COMT) have been shown to modulate proliferation and angiogenesis of granulosa cells. Objective: The objective of the study was to evaluate COMT ovarian expression as well as the production of estrogen metabolites (2-hydroxyestrogen and 2-methoxyestrogen) in subjects with PCOS. Design: Immunohistochemistry was used to assess COMT expression in ovarian tissues. Urinary levels of 10 different estrogens and estrogen metabolites were measured using enzyme-labeled immunoassays and/or liquid chromatography with tandem mass spectrometry. Setting: The study was conducted at a tertiary university referral center. Patients and Other Participants: Ovarian tissues were obtained from six control subjects and six subjects with PCOS. Fasting first-void urinary samples were collected from 49 subjects with PCOS and 36 healthy control subjects. Main Outcome Measure(s): COMT protein expression in ovarian tissues was measured. Urinary levels of 2-hydroxyestrogen and 2-methoxyestrogen levels in PCOS patients were also measured. Results: Whereas immunohistochemistry showed that COMT was expressed in ovaries from control and PCOS subjects, its expression was significantly higher in ovaries from subjects with PCOS, in both the follicular structures and ovarian stroma. The urinary 2-hydroxyestrogen level was significantly lower in subjects with PCOS, compared with normal controls (P = 0.009). Additionally, urinary 2-hydroxyestrogen levels negatively correlated with serum insulin levels in subjects with PCOS (r = -0.333, P =0 .031). Conclusions: Urinary 2-hydroxyestrogen is decreased in subjects with PCOS, which could be due in part to increased ovarian expression of COMT. Further studies are needed to ascertain the role of estrogen metabolism in PCOS before this information can be used in clinical settings.

UR - http://www.scopus.com/inward/record.url?scp=34547823580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547823580&partnerID=8YFLogxK

U2 - 10.1210/jc.2006-2719

DO - 10.1210/jc.2006-2719

M3 - Article

C2 - 17535988

AN - SCOPUS:34547823580

VL - 92

SP - 3285

EP - 3291

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 8

ER -